Variability of insulin requirements over 12 weeks of closed-loop insulin delivery in adults with type 1 diabetes

Diabetes Care

Volumn 39, Issue 5, 2016, Pages 830-832

  Ruan, Yue ^a   Thabit, Hood ^a   Leelarathna, Lalantha ^a   Hartnell, Sara ^a   Willinska, Malgorzata E ^a   Dellweg, Sibylle ^b   Benesch, Carsten ^b   Mader, Julia K ^c   Holzer, Manuel ^c   Kojzar, Harald ^c   Evans, Mark L ^a   Pieber, Thomas R ^c   Arnolds, Sabine ^c   Hovorka, Roman ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Profil   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLOSED LOOP INSULIN DELIVERY; DOSE RESPONSE; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; INSULIN INFUSION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84964720111     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2623     Document Type: Article

References (13)

1. Thabit H, Hovorka R. Bringing closed-loop home: recent advances in closed-loop insulin delivery. Curr Opin Endocrinol Diabetes Obes 2014;21:95-101
2. Thabit H, Tauschmann M, Allen JM, et al.; APCam Consortium; AP@home Consortium. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015;373:2129-2140
3. Kropff J, Del Favero S, Place J, et al.; AP@home Consortium. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 2015;3:939-947
4. Nimri R, Muller I, Atlas E, et al. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 2014;37:3025-3032
5. Elleri D, Allen JM, Harris J, et al. Absorption patterns of meals containing complex carbohydrates in type 1 diabetes. Diabetologia 2013;56:1108-1117
6. Davey RJ, Howe W, Paramalingam N, et al. The effect of midday moderate-intensity exercise on postexercise hypoglycemia risk in individuals with type 1 diabetes. J Clin Endocrinol Metab 2013;98:2908-2914
7. Haidar A, Elleri D, Kumareswaran K, et al. Pharmacokinetics of insulin aspart in pumptreated subjects with type 1diabetes: reproducibility and effect of age, weight, and duration of diabetes. Diabetes Care 2013;36:e173-e174
8. Luijf YM, Arnolds S, Avogaro A, et al.; AP@home Consortium. Patch pump versus conventional pump: postprandial glycemic excursions and the influence of wear time. Diabetes Technol Ther 2013;15:575-579
9. Heinemann L, Hirsch L, Hovorka R. Lipohypertrophy and the artificial pancreas: is this an issue? J Diabetes Sci Technol 2014;8:915-917
10. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002;18:192-200
11. Brown SA, Jiang B, McElwee-Malloy M, Wakeman C, Breton MD. Fluctuations of hyperglycemia and insulin sensitivity are linked to menstrual cycle phases in women with T1D. J Diabetes Sci Technol 2015;9:1192-1199
12. Cryer PE. Glycemic goals in diabetes: tradeoff between glycemic control and iatrogenic hypoglycemia. Diabetes 2014;63:2188-2195
13. Yardley JE, Kenny GP, Perkins BA, et al. Resistance versus aerobic exercise: acute effects on glycemia in type 1 diabetes. Diabetes Care 2013;36:537-542